Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
NCT06569147
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
49
Enrollment
OTHER
Sponsor class
Conditions
AL Amyloidosis
Interventions
DRUG:
Elranatamab
Sponsor
Brigham and Women's Hospital